Your browser does not support JavaScript!



[2019/07/10] Having identified the most effective inhibitor of the side-effects of CAR-T type drugs, Professor Huang and his team were awarded the “National Emblem Award”

National Yang Ming University Institute of Biotechnology in Medicine doctoral student Tsai (Middle) accepting the “National Emblem Award” at the PPSSC international conference


Doctoral student Tsai, Department of Biotechnology and Laboratory Science in Medicine, and Vietnamese intern Doan Hien, Institute of Biopharmaceutical Sciences, who were led by Professor Huang, Institute of Biopharmaceutical Sciences, identified three drugs that are able to effectively inhibit the side effects of the CAR-T type drugs. During the 12th annual Pan Pacific Symposium on Stem Cells and Cancer Research, they were awarded the “National Emblem Award”.


The Pan Pacific Symposium on Stem Cells and Cancer Research, sponsored by the Stem Cell and Regenerative Medicine Education Foundation, gathers clinicians, experts, scholars, members of industry and government officials together from around the world. The symposium serves as a platform to share with the world major innovation breakthroughs and latest regulations in the field of cellular treatment. The “National Emblem Award” serves to recognize excellence among young scientists that results in innovation and achievement to this field of research. The 12th Annual conference was held FROM May 3rd to May 5th at Hualien Tzu Chi Hospital.


Student Tsai remarked that the development of any new drug is a very long process and the ability to use our research our laboratory’s internal drug screening platform to successfully identify the drugs mentioned above is an important step forward. One of the drugs pinpointed is a drug that has been in use for many years clinically. By giving an old drug a new application it is possible to drastically save on the expense and time required when developing new drugs. In addition, older drugs, when compared to new drugs, are safer and this is able to accelerate the process of moving from clinical trials to use in medicine generally. She also stated how grateful she was to all the people who offered help and guidance during the research. She felt very honored to be recognized by the organizers and the judges for this award and further indicated that she was very pleased that the screening platform established by the team has been confirmed to be a useful tool for the future.


Vietnamese Intern Doan Hien Ly of the Institute of Biopharmaceutical (left) and doctoral student Tsai of the Institute of Biotechnology in Medicine.